Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: Results from the hd2000 GISL trial

Fortunato Morabito, Stefan Hohaus, Corrado Mammi, Luigi Marcheselli, Massimo Gentile, Francesco Merli, Antonella Montanini, Caterina Stelitano, Antonio La Sala, Renato Scalone, Maria Teresa Voso, Stefano Luminari, Emilio Iannitto, Paolo Gobbi, Massimo Federico

Research output: Contribution to journalArticle

Abstract

Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens. Carriers of the GSTP1Ile105Val polymorphism had a higher rate of grade 3-4 anemia following treatment. Overall, our study failed to validate GST genotyping as prognostic factor for progression-free survival (PFS). Only the small cohort of patients with an international prognostic score (IPS) >3 and undeleted GSTT1 and/or GSTM1, treated with ABVD had worse progression-free survival (PFS) (GSTT1 + vs GSTT1-: HR 5.02, 95% C.I., 1.1621.8, p = 0.031, GSTM1 + /GSTT1 + vs GSTM1-and/or GSTT1-: HR 4.61, 95% C.I. 1.28 16.6, p = 0.019, respectively). No differences were observed for patients treated with intensified regimens, as BEACOPP and CEC. In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen.

Original languageEnglish
Pages (from-to)406-410
Number of pages5
JournalLeukemia and Lymphoma
Volume53
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Glutathione Transferase
Hodgkin Disease
Disease-Free Survival
Anemia
Lymphoma
Therapeutics

Keywords

  • GSTM1
  • GSTT1
  • Hodgkin's lymphoma
  • Polymorphism
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma : Results from the hd2000 GISL trial. / Morabito, Fortunato; Hohaus, Stefan; Mammi, Corrado; Marcheselli, Luigi; Gentile, Massimo; Merli, Francesco; Montanini, Antonella; Stelitano, Caterina; Sala, Antonio La; Scalone, Renato; Voso, Maria Teresa; Luminari, Stefano; Iannitto, Emilio; Gobbi, Paolo; Federico, Massimo.

In: Leukemia and Lymphoma, Vol. 53, No. 3, 03.2012, p. 406-410.

Research output: Contribution to journalArticle

Morabito, F, Hohaus, S, Mammi, C, Marcheselli, L, Gentile, M, Merli, F, Montanini, A, Stelitano, C, Sala, AL, Scalone, R, Voso, MT, Luminari, S, Iannitto, E, Gobbi, P & Federico, M 2012, 'Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: Results from the hd2000 GISL trial', Leukemia and Lymphoma, vol. 53, no. 3, pp. 406-410. https://doi.org/10.3109/10428194.2011.623254
Morabito, Fortunato ; Hohaus, Stefan ; Mammi, Corrado ; Marcheselli, Luigi ; Gentile, Massimo ; Merli, Francesco ; Montanini, Antonella ; Stelitano, Caterina ; Sala, Antonio La ; Scalone, Renato ; Voso, Maria Teresa ; Luminari, Stefano ; Iannitto, Emilio ; Gobbi, Paolo ; Federico, Massimo. / Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma : Results from the hd2000 GISL trial. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 3. pp. 406-410.
@article{a39763ca5c284e30be4e811c5bae601c,
title = "Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: Results from the hd2000 GISL trial",
abstract = "Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens. Carriers of the GSTP1Ile105Val polymorphism had a higher rate of grade 3-4 anemia following treatment. Overall, our study failed to validate GST genotyping as prognostic factor for progression-free survival (PFS). Only the small cohort of patients with an international prognostic score (IPS) >3 and undeleted GSTT1 and/or GSTM1, treated with ABVD had worse progression-free survival (PFS) (GSTT1 + vs GSTT1-: HR 5.02, 95{\%} C.I., 1.1621.8, p = 0.031, GSTM1 + /GSTT1 + vs GSTM1-and/or GSTT1-: HR 4.61, 95{\%} C.I. 1.28 16.6, p = 0.019, respectively). No differences were observed for patients treated with intensified regimens, as BEACOPP and CEC. In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen.",
keywords = "GSTM1, GSTT1, Hodgkin's lymphoma, Polymorphism, Prognosis",
author = "Fortunato Morabito and Stefan Hohaus and Corrado Mammi and Luigi Marcheselli and Massimo Gentile and Francesco Merli and Antonella Montanini and Caterina Stelitano and Sala, {Antonio La} and Renato Scalone and Voso, {Maria Teresa} and Stefano Luminari and Emilio Iannitto and Paolo Gobbi and Massimo Federico",
year = "2012",
month = "3",
doi = "10.3109/10428194.2011.623254",
language = "English",
volume = "53",
pages = "406--410",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma

T2 - Results from the hd2000 GISL trial

AU - Morabito, Fortunato

AU - Hohaus, Stefan

AU - Mammi, Corrado

AU - Marcheselli, Luigi

AU - Gentile, Massimo

AU - Merli, Francesco

AU - Montanini, Antonella

AU - Stelitano, Caterina

AU - Sala, Antonio La

AU - Scalone, Renato

AU - Voso, Maria Teresa

AU - Luminari, Stefano

AU - Iannitto, Emilio

AU - Gobbi, Paolo

AU - Federico, Massimo

PY - 2012/3

Y1 - 2012/3

N2 - Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens. Carriers of the GSTP1Ile105Val polymorphism had a higher rate of grade 3-4 anemia following treatment. Overall, our study failed to validate GST genotyping as prognostic factor for progression-free survival (PFS). Only the small cohort of patients with an international prognostic score (IPS) >3 and undeleted GSTT1 and/or GSTM1, treated with ABVD had worse progression-free survival (PFS) (GSTT1 + vs GSTT1-: HR 5.02, 95% C.I., 1.1621.8, p = 0.031, GSTM1 + /GSTT1 + vs GSTM1-and/or GSTT1-: HR 4.61, 95% C.I. 1.28 16.6, p = 0.019, respectively). No differences were observed for patients treated with intensified regimens, as BEACOPP and CEC. In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen.

AB - Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens. Carriers of the GSTP1Ile105Val polymorphism had a higher rate of grade 3-4 anemia following treatment. Overall, our study failed to validate GST genotyping as prognostic factor for progression-free survival (PFS). Only the small cohort of patients with an international prognostic score (IPS) >3 and undeleted GSTT1 and/or GSTM1, treated with ABVD had worse progression-free survival (PFS) (GSTT1 + vs GSTT1-: HR 5.02, 95% C.I., 1.1621.8, p = 0.031, GSTM1 + /GSTT1 + vs GSTM1-and/or GSTT1-: HR 4.61, 95% C.I. 1.28 16.6, p = 0.019, respectively). No differences were observed for patients treated with intensified regimens, as BEACOPP and CEC. In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen.

KW - GSTM1

KW - GSTT1

KW - Hodgkin's lymphoma

KW - Polymorphism

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84857509185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857509185&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.623254

DO - 10.3109/10428194.2011.623254

M3 - Article

C2 - 21916526

AN - SCOPUS:84857509185

VL - 53

SP - 406

EP - 410

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -